Suppressing DUX4 is currently the focus of several studies/trials into potential therapeutic strategies for FSHD (65–67) and so muscle-localized immune cells, as well as myogenic cells, may need to be targeted. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.